Eylea® Intravitreal Injection for Clinics

Eylea® is an ophthalmic anti-VEGF preparation used in retina services for intravitreal therapy. Clinics maintain this product to support injection workflows for neovascular macular conditions and retinal vein occlusion programs, with US distribution. Med Wholesale Supplies serves licensed clinics and healthcare professionals with authentic, brand-name medical products sourced through vetted distributors.

What Eylea Is and How It Works

This sterile solution is supplied for intravitreal administration in a single-use vial. It contains aflibercept, a recombinant fusion protein that binds VEGF-A, VEGF-B, and PlGF in the vitreous. By sequestering these ligands, the agent supports clinic-managed retina protocols that aim to stabilize fluid dynamics in affected eyes. As an Aflibercept 2 mg injection, the preparation aligns with dosing frameworks commonly defined by retina specialists and pharmacy leadership. For additional program planning resources, explore Ophthalmology on our platform.

Ensure aseptic, intravitreal technique consistent with your facility’s policies. Monitor for injection-related events per your oversight procedures, including intraocular pressure checks and post-procedure assessments. This product is intended for use by trained ophthalmic teams familiar with intravitreal workflows and adverse event surveillance.

Professional Applications

Retina clinics integrate this agent into scheduled injection days that include imaging review, informed consent, antisepsis, and standardized documentation. The Eylea 2 mg vial format complements single-dose, intravitreal use with sterile draping and site preparation. Many practices also synchronize pharmacy handoff, lot tracking, and nursing checklists to keep throughput predictable across sessions. Where appropriate and per physician direction, supporting ocular medications may be incorporated; see TobraDex Suspension for adjunctive care decisions defined by your protocols.

Key Features

• Single-use presentation: sterile intravitreal vial for one patient encounter.
• Anti-VEGF class: recombinant fusion protein designed to bind key angiogenic ligands.
• Ready-to-use solution: no reconstitution steps, supporting efficient room turnover.
• Accessories included: draw needle, 5-micron filter needle, 30 G 1/2-inch injection needle, and 1-mL syringe.
• Clear identification: product, lot, and expiry appear on primary packaging for traceability.
• Non-English carton and leaflet: suitable for teams accustomed to international-language labeling.
• Workflow fit: aligns with established retina clinic processes and ASC protocols.
• Secure presentation: tamper-evident components support chain-of-custody practices.
• Program breadth: compatible with common retina service lines listed under Pharmaceuticals.

Benefits in Practice

This product supports predictable intravitreal days by arriving as a single-use unit with core accessories. Staff can set up trays quickly, maintain consistent technique, and streamline chair-time transitions. The included filter needle helps standardize preparation steps, while the fine-gauge injection needle supports the final intravitreal administration per your physician’s protocol.

Standardized packaging helps inventory teams execute lot capture, expiry checks, and reconciliation without added repack steps. Pharmacy can allocate units to procedure rooms with minimal kitting, reducing variability across locations. Clinical managers gain flexibility to schedule personnel and rooms with confidence, balancing imaging, injection, and post-visit monitoring. For broader context on retina programs, see our article HD Therapy Guide and additional clinic education such as Ophthalmic Insights.

Composition & Ingredients

Active: aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B, and PlGF. The solution is provided for intravitreal administration as supplied by the manufacturer.

Excipients: formulation excipients are provided in the official package insert. Review the enclosed leaflet and your institution’s formulary references for a complete list. Use according to your clinic’s policies and applicable labeling.

Packaging & Supply

This listing reflects international labeling with non-English materials. Please ensure your team reviews the leaflet and carton details during receiving and pharmacy check-in. If your facility requires English-only labeling for staff training or documentation consistency, see the Comparable Products section below.

• 1 x single-dose vial intended to deliver 2 mg in 0.05 mL for intravitreal use.
• 1 x 18-gauge × 1½-inch draw needle.
• 1 x 5-micron filter needle.
• 1 x 30 G 1/2-inch injection needle.
• 1 x 1-mL sterile syringe.

Facilities choosing Eylea non English packaging should confirm that intake, storage, and administration teams are comfortable with the carton language and insert format. For guidance on needle selection and tray setup, see our Needles Guide.

Ordering & Logistics

Create or verify your professional account to view inventory allocation and request units. Sign in to enable volume and contract pricing workflows and to designate authorized ship-to locations. Your order history and lot tracking support clinic documentation and compliance routines.

We coordinate fulfillment with attention to product handling requirements and clinic scheduling. You can designate preferred delivery windows and add PO references for reconciliation. Our team confirms license status and any additional documentation your state or facility may require before release.

Comparable Products

Clinics that prefer English-labeled packaging can consider our English Alternative within the same product line. Some teams also standardize around prefilled formats for workflow reasons; if that aligns with your protocol, note the related packaging in Eylea 2 mg/0.05 mL prefilled syringe discussions. For broader ophthalmic selections, review Ophthalmology to complement your injection day needs.

Pricing & Access

Sign in to view tiered pricing based on order volumes and contracted terms. Your account dashboard enables quote requests, formulary notes, and scheduling preferences. If your service line uses prefilled formats alongside vials, indicate interest in Eylea PFS 2 mg so our team can align allocation with your monthly injection volume.

Availability & Substitutions

Inventory may vary due to manufacturer releases and regional demand. If your preferred packaging or label language is not available, our team will present clinically appropriate alternatives and confirm substitutions with your pharmacy or medical director before fulfillment. We do not guarantee restock dates, and we recommend proactive ordering for multi-site retina schedules.

Authoritative Sources

• Manufacturer HCP Site
• FDA Prescribing Information
• MedlinePlus Aflibercept

Key Safety Considerations

Use intravitreal aseptic technique and institute post-injection monitoring consistent with your protocol. Adverse reactions reported with this class can include ocular redness, discomfort, cataract progression, vitreous floaters or detachment, and transient increases in intraocular pressure. Educate patients on symptoms that warrant urgent evaluation in your clinic. Always consult current labeling and your institution’s procedures before administration.

Closing

Sign in to confirm allocation and scheduling preferences for your retina program, supported by temperature-controlled handling when required and tracked US delivery.